Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21362075 | 0.90 | TP53 (0.40) | KMT2ATP53MAPTRAB9AKCNH2 | |
| SCHEMBL20158009 | 0.78 | GAA (0.38) | KMT2ATP53MAPTRAB9AKCNH2 | |
| SCHEMBL20158012 | 0.73 | PPARG (0.40) | KMT2ATP53MAPTRAB9AKCNH2 | |
| SCHEMBL20157979 | 0.72 | MAPT (0.43) | KMT2ATP53MAPTRAB9AALDH1A1 | |
| SCHEMBL20157905 | 0.71 | POLB (0.32) | GAAALDH1A1SMN1; SMN2POLB | |
| SCHEMBL21362614 | 0.71 | TP53 (0.52) | KMT2ATP53MAPTRAB9AKCNH2 | |
| SCHEMBL10599055 | 0.71 | SRD5A2 (0.54) | KMT2ATP53MAPTRAB9ASRD5A2 | |
| SCHEMBL20157693 | 0.71 | MAPT (0.49) | KMT2AMAPTRAB9ASRD5A2ALDH1A1 | |
| SCHEMBL20157971 | 0.71 | NPC1 (0.44) | KMT2ATP53MAPTRAB9AKCNH2 | |
| SCHEMBL21362160 | 0.71 | MAPT (0.36) | KMT2AMAPTRAB9AKCNH2SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190284192-A1 | NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284192-A1 | NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | MYC, BRD1, BRD3 | KMT2A 1082/4885TP53 197/4885MAPT 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.